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Skeletal muscle contains Pax7-expressing muscle
stem or satellite cells, enabling muscle regeneration
throughout most of adult life. Here, we demonstrate
that induced inactivation of Pax7 in Pax7-expressing
cells of adult mice leads to loss of muscle stem cells
and reduced heterochromatin condensation in rare
surviving satellite cells. Inactivation of Pax7 in
Myf5-expressing cells revealed that the majority of
adult muscle stem cells originate from myogenic
lineages, which express the myogenic regulators
Myf5 or MyoD. Likewise, the majority of muscle
stem cells are replenished from Myf5-expressing
myogenic cells during adult life, and inactivation of
Pax7 in Myf5-expressing cells after muscle damage
leads to a complete arrest of muscle regeneration.
Finally, we demonstrate that a relatively small num-
ber of muscle stem cells are sufficient for efficient
repair of skeletal muscles. We conclude that Pax7




Adult skeletal muscle is subject to continuous regeneration,
especially after injury or excessive physical training. Muscle
regeneration is primarily mediated by a distinct population of
muscle-specific adult stem cells known as satellite cells (SCs),
which are located between the basal lamina and sarcolemma
of muscle fibers (Shi and Garry, 2006). Stem cells express the
paired box transcription factor Pax7 (Seale et al., 2000) and
are thought to originate from mesodermal cells expressing
Pax7 and its paralogue Pax3 during embryogenesis (Kassar-
Duchossoy et al., 2005; Relaix et al., 2005). Deletion of Pax7 in
mice leads to normal numbers of stem cells at birth followed
by excessive wasting of stem cells during the first weeks of post-
natal development (Oustanina et al., 2004; Relaix et al., 2006).
Emerging evidence indicates that heterogeneity exists within
the Pax7-expressing stem cell niche and it was recently postu-
lated that adult stem cells, unlike neonatal muscle progenitor590 Cell Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Incells, do not require Pax7 either for stem cell maintenance or
for regeneration of acutely injured skeletal muscle over a short
period (Lepper et al., 2009).
At present the position of Pax7 in the genetic network that
directs myogenesis is disputed (Braun and Gautel, 2011).
Concomitant genetic inactivation of Pax7 and Pax3 disrupts
somite development and myogenesis after E10.5 in mice,
although initial formation of the myotome and expression of
the myogenic regulatory factor Myf5 is present in Pax3/Pax7
double mutants (Relaix et al., 2005), indicating that early Myf5
activation occurs independently of Pax3/Pax7. Conversely,
Myf5/MyoD/Mrf4 compound mutants do not form the myogenic
lineage (Rudnicki et al., 1993) and hence fail to express Pax7. On
the other hand, there is ample evidence for direct and indirect
activation of Myf5 by Pax3 during embryogenesis (reviewed by
Braun andGautel, 2011).Moreover, Pax7 seems to directly regu-
late Myf5 expression in satellite-cell-derived myoblasts by
recruitment of a histone methyltransferase (HMT) complex
(McKinnell et al., 2008). Yet, 10% of Pax7-expressing SCs,
which have never expressed Myf5, show a privileged contri-
bution to the SC compartment compared to Pax7-positive,
Myf5-expressing cells indicating heterogeneity within the SC
population (Kuang et al., 2007).
Critically missing from previous studies is the role of Pax7 in
long-term maintenance and expansion of these heterogeneous
populations of muscle stem cells defined by Myf5 expression.
Here, we show that inactivation of Pax7 during SC proliferation
dramatically reduced the number of SCs and prevented muscle
regeneration. Our results revealed an essential function of Pax7
in maintenance of heterochromatin and expansion of SCs, giving
rise to a newmodel of the regulatory network betweenmyogenic
genes and Pax7 that drives muscle regeneration.RESULTS
Conditional Deletion of the Pax7 Gene in Adult Skeletal
Muscle Leads to Delayed Loss of SCs
To analyze the role of Pax7 in adult muscle stem cells, we inac-
tivated the Pax7 gene in adult mice by treating 3-month-old
Pax7CE/loxP-Gu mice (n = 3) and Pax7loxP-Gu/+ controls (n = 3)
with 3 mg tamoxifen (TAM) per 40 g body weight for 5 days
(Lepper et al., 2009). The novel conditional Pax7 allele
(Pax7loxP-Gu/loxP-Gu), which we used for this experiment, allows
Cre-recombinase-mediated deletion of the transcriptional startc.
Figure 1. Loss of Muscle Satellite Cells after Postnatal Inactivation of Pax7
Pax7CE/loxP-Gu and Pax7loxP-Gu/+ littermates (n = 3, in each group) were treated with TAM for 5 days. Muscle tissues were analyzed at different time points as
indicated.
(A–L) Hematoxylin/Eosin (HE) staining of muscle tissue sections from TAM-treated Pax7CE/loxP-Gu and Pax7loxP-Gu/+ mice at 1 day (A–C and G–I) and 2 months
(D–F and J–L).
(M) Statistical evaluation of cross-sectional areas (CSA) of muscle fibers of TAM-treated Pax7CE/loxP-Gu and Pax7loxP-Gu/+ mice at different time points.
(N and O) Analysis of remaining SC numbers. SCs situated on isolatedmyotubes (n > 150) were identified by being stained with Pax7 (N) and CD34 (O) antibodies.
SC numbers were calculated relative to the number of myonuclei (DAPI).
Error bars represent standard deviation of the mean (t test: n.s. = not significant; ***p < 0.001; *p < 0.05). Scale bar: (A)–(L) = 20 mm. See also Figures S1 and S2.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem Cellssite and the first three exons, preventing generation of an mRNA
from the Pax7 locus (Figures S1A and S1B available online).
Notably, generation of CMV-Cre/Pax7loxP-Gu/loxP-Gu mice, in
which the Pax7 gene is deleted early during development, fully
phenocopied the Pax7 germline knockout (Figure S2) (Ousta-
nina et al., 2004), confirming that Cre-recombinase-mediated
recombination generates a null allele. We observed a massive
reduction, but not complete loss, of Pax7-positive SCs on iso-
lated myofibers of Pax7CE/loxP-Gu mice already 1 day after the
end of the TAM treatment (Figure 1N). Concomitant with the
loss of Pax7-positive SCs, we also noted a rapid decline of
Pax7 mRNA concentrations in TAM-treated Pax7CE/loxP-Gu
mice (Figures S3A and S3F) and a rapid decline of SCs as
assessed by the expression of calcitonin receptor (Calcr), a
marker of quiescent SCs (Figure S3B) (Fukada et al., 2007). Sur-
prisingly, when we used CD34 expression to assess SCs in
these mice, virtually unchanged numbers of CD34-positive
SCs were found 1 day (1d), 7d, and 14d after the end of the
TAM treatment (Figure 1O). Thus, it appeared that inactivation
of Pax7 led to differential changes of the SC signature. Impor-
tantly, the number of these Pax7-negative, CD34-positive SCs
declined dramatically at 30d and 60d, suggesting that SCs afterCellloss of Pax7 expression maintain some SC features for several
weeks, but not indefinitely (Figure 1O; Figure S3F). At all time
points TAM treatment did not affect morphological characteris-
tics of skeletal muscles since no centrally localized nuclei indic-
ative of regenerated muscle (Figures 1A–1L) or differences in
fiber diameter indicative of muscle wasting (Figure 1M) were
observed.
Pax7 Is Required during SC Expansion to Achieve
Efficient Skeletal Muscle Regeneration
Next, we induced muscle regeneration 1 day after completion of
the 5-day TAM regimen by injection of Cardiotoxin (CTX) into the
Tibialis anterior (T.A.) muscle. Surprisingly, we detected a signif-
icant regenerative response resulting in the formation of multiple
regenerated muscle fibers with centrally located nuclei (Figures
2C and 2F) despite a reduction of Pax7-positive SCs in TAM-
treated Pax7CE/loxP-Gu mice by 97.80% ± 0.47% (n = 3)
15 days after the end of the regimen (Figure 2S). However, regen-
erated T.A. of TAM-treated Pax7CE/loxP-Gu mice (Figure 2C)
showed a reduction of the total muscle size and of diameters
of individual myofibers compared to TAM-treated Pax7loxP-Gu/+
mice and undamaged controls (Figures S3D and S3E).Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inc. 591
Figure 2. Impaired Muscle Regeneration in Adult Mice after Enhanced Inactivation of Pax7
(A–F, G–L, and M–R) Morphological analysis of T.A. muscles of TAM-treated Pax7CE/loxP-Gu and Pax7loxP-Gu/+ mice injected with CTX to induce muscle regen-
eration. TAM treatment regimens and time points of analysis are indicated at the top of each panel. (A–F) HE staining of T.A. muscles of 12-week-old mice (n = 3)
14 days after CTX injection. Cre-recombinase-mediated inactivation ofPax7was induced by five consecutive TAM injections. (G–R) HE staining of T.A. muscles of
20-week-old mice (n = 3), which received additional administration of TAM after one (H and K) or two (I and L) rounds of muscle regeneration. TAM was
administered before and during the first round of muscle regeneration (G and L) or before and during two rounds of muscle regeneration (M–R). (S–U) Number of
Pax7-positive and CD34-positive SC populations on isolated myofibers relative to the number of myonuclei (DAPI). Error bars represent standard deviation of the
mean (t test: ***p < 0.001). Scale bar: overview = 200 mm; magnification = 25 mm. See also Figure S3.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem CellsTo answer the question of whether loss of Pax7 expression
during the repair process would further compromise regenera-
tion of skeletal muscle, we modified our experimental conditions
as follows: (1) we constantly administered TAM before and dur-
ing initiation of skeletal muscle injury to stimulate and sustain592 Cell Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier InTAM-dependent recombination and hence deletion of the con-
ditional Pax7 allele (Figures 2G–2L); and (2) we introduced an
additional round of CTX injection either before or during TAM
administration to further challenge the regenerative response
(Figures 2M–2R). Sustained stimulation of Pax7 deletion inc.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem Cells3-month-old mice during muscle regeneration compromised
the regenerative capacity more severely compared to mice in
which induction of Pax7 deletion was terminated before onset
of regeneration (Figures 2A–2F, 2G–2L, and 2M–2R), although
no further decline of Pax7-positive SCs occurred (94.70% ±
2.24% reduction after continuous TAM treatment [n = 6]
compared to 97.80% ± 0.47% [n = 3] reduction after initial
TAM treatment) (Figures 2S, 2T, and 2U and Figures S3C and
S4A). We observed a massive increase of both necrotic fibers
and fibrotic tissue resulting in a reduction of size of the regener-
ating T.A. in contrast to control mice (Figures 2H, 2I, 2N, and 2O
and Figures S4K–S4P). Similar results were obtained using 6-
week-old mice (n = 3) (Figures S4B–S4J). Control experiments
without TAM using Pax7loxP-Gu/+ and Pax7CE/loxP-Gu mice re-
vealed that repeated rounds of muscle damage did not affect
the number of Pax7-positive SCs without induction of Pax7 dele-
tion (Figure S4Q). Our results demonstrate that continuous
expression of Pax7 in SCs during muscle regeneration is essen-
tial for efficient muscle repair.
Inactivation of Pax7 in Adult Skeletal Muscle Gives Rise
to Rare Atypical SCs with Reduced Heterochromatin
Condensation
The differential results obtained by using Calcr versus CD34 to
assess mutant cells in a short-term assay and the long-term
survival of CD34-positive mutant cells suggested that Pax7
maintains an unknown aspect of SC properties. We therefore
investigated the ultrastructure of SCs by electron microscopy
(EM), which also represents the most reliable method for deter-
mining SC numbers. Under physiological conditions SCs can
be readily identified as small, heterochromatin-rich cells that
reside between the basal lamina and sarcolemma (Figure 3A)
(Oustanina et al., 2004; Shi and Garry, 2006). By this criterion,
Pax7CE/loxP-Gu mice treated with the extended TAM regimen
showed a dramatic reduction of SCs in the T.A. muscle (0.48%
out of 207 nuclei) compared to nontreated or TAM-treated WT
controls (7.85% out of 191 nuclei and 8.48% out of 224 nuclei,
respectively) 14 days after completion of TAM administration
(Figures 3D and 3F). Similarly, we found only a very low number
of SCs in TAM-treated Pax7CE/loxP-Gu mice in regenerated mus-
cles 14 days after CTX-induced damage (0.34% out of 251
nuclei) (Figures 3D and 3F). We were intrigued to see that the
reduction of SCs after Pax7 inactivation as determined by EM
corresponded to the remaining number of Pax7-expressing
SCs (Figure 1N) (94.3% reduction by EM versus 97.80% reduc-
tion by Pax7 immunofluorescence) but not to the number of
CD34-positive SCs (Figure 1O). Of note, SCs detected in contin-
uously TAM-treated Pax7CE/loxP-Gu mice lacked characteristic
heterochromatin condensations and contained an abnormal
amount of cytoplasm and organelles (Figure 3B). Such atypical
SCs were not found in WT control mice.
Previous studies suggested that inactivation of Pax7 in adult
mice does not reduce SC number and has no aberrant effect
on muscle regeneration in temporary assays (Lepper et al.,
2009). The previously reported conditional Pax7loxP-Le allele (Fig-
ure S1C) theoretically allows generation of a truncated transcript
by the splicing of exon I to exon III, since only exon II is deleted by
Cre recombinase (Lepper et al., 2009). In fact, RT-PCR analysis
of the TAM-treated Pax7CE/loxP-Le mutant strain revealed theCellpresence of a truncated Pax7mRNA in skeletal muscles (Figures
S1C and S1D) (Lepper et al., 2009). Furthermore, overexpression
of a C- and N-terminal-tagged Pax7 cDNA construct lacking
exon II in HEK293T cells yielded a shortened protein, presum-
ably initiated at a downstream ATG and predicted to contain
the functional homeodomain, suggesting that the Pax7loxP-Le
allele may retain residual biological activity after exon II deletion
(Figures S1C–S1E) (Soleimani et al., 2012).
We next investigated the number and morphology of SCs in
the Pax7CE/loxP-Le strain by EM instead of using markers. EM
analysis unraveled a 50.34% to 62.01% reduction of SCs 14d
after TAM administration in TAM-treated Pax7CE/loxP-Le mice
(Figures 3E and 3F). Intriguingly, we also detected the same
atypical SCs characterized by loss of heterochromatin con-
densation found in Pax7CE/loxP-Gu mice (Figure 3C). Atypical
SCs represent a significant share of remaining SCs (25% of all
SCs in Pax7CE/loxP-Le and 83% in Pax7CE/loxP-Gu mice 14d after
initial 5d TAM treatment), although absolute numbers are low
(0.53% in Pax7CE/loxP-Le and 0.57% in Pax7CE/loxP-Gu mice
related to the number of myonuclei; Figure S3G). Therefore,
these atypical SCs cannot fully account for the Pax7-negative,
CD34-positive SC population, which exists early after Pax7
deletion (Figures 1N and 1O). Sixty days after TAM treatment,
the number of SCs had declined further in Pax7CE/loxP-Le mice,
resulting in an 82.41% loss of SCs. Interestingly, direct compar-
ison of EM-counted SCs in Pax7CE/loxP-Gu and Pax7CE/loxP-Le
strains at 14d (including atypical SCs) revealed significant
differences of SC numbers between both strains with a more
pronounced loss of SCs in the Pax7CE/loxP-Gu compared to the
Pax7loxP-Le strain (94.3% versus 50.34% in undamaged muscle)
(Figures 3D–3F). Hence, regardless of which conditional allele
was used, EM revealed a consistent and profound change in
SC number and property not found by conventional marker
analysis.
The differential decline of SC numbers in Pax7CE/loxP-Gu versus
Pax7CE/loxP-Le suggested that the truncated Pax7 mRNA in
Pax7CE/loxP-Le mice exerts a residual biological activity, which
suffices to delay loss of SCs. In contrast, the complete loss of
Pax7 mRNA expression in Pax7CE/loxP-Gu mice resulted in a
more rapid loss of SCs. To determine the critical threshold after
which the residual biological activity of the Pax7CE/loxP-Le
becomes unable to support efficient generation of new myofib-
ers, we determined the number of Pax7-lineage-traced SCs by
X-gal staining in Pax7CE/loxP-Le/Rosa26lacZ mice 14d, 30d, 60d,
90d, and 240d after completion of TAM administration. Interest-
ingly, we detected an increasing loss of SCs, which reached
a maximum at 240d (Figure 4C). The decline of SCs at 90d and
240d corresponded to impaired skeletal muscle regeneration
at 90d, 150d, and 240d post TAM administration (Figure 4A).
Next, we determined whether residual SCs at 240d post TAM
administration were still able to contribute to the formation of
myofibers, which occasionally formed 10d after CTX-induced
muscle injury. LacZ staining revealed very few, thin myotubes
in regenerating muscle, which were derived from marked SCs
(Figure 4B), reinforcing the concept of an absolute requirement
of SCs for skeletal muscle regeneration (Lepper et al., 2011;
Murphy et al., 2011; Sambasivan et al., 2011). We concluded
that the degree of Pax7 activity critically affects SC function
and muscle regeneration and that delayed decline of SCs and/orStem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inc. 593
Figure 3. Loss of SCs in Adult Mice Differs between Pax7 Conditional Alleles
(A–C) EM microphotographs of ultrathin muscle sections used for quantification of SCs in mice in Pax7CE/loxP-Gu allele (A) and Pax7CE/loxP-Le mice (C). (B and C)
The majority of remaining SCs in Pax7CE/loxP-Le mutant mice are localized under the basal lamina as regular SCs but show a strong reduction of heterochromatin
(C). Similar atypical stem cells were also present in Pax7CE/loxP-Gu mice but only shortly after Pax7 inactivation (B).
(D) Number of SCs relative to myonuclei in undamaged and regenerated T.A. muscles of Pax7CE/loxP-Gu and Pax7loxP-Gu/+ mice 14 days after CTX injection. TAM
was administered for 5 days before regeneration in the +TAM group. Numbers in brackets indicate the number of counted myonuclei, e.g., only a single SC was
detected in TAM-treated Pax7CE/loxP-Gu mutants.
(E) Comparison of the number of SCs 14 days after Pax7 deletion reveals differences in remaining SCs between the Pax7CE/loxP-Gu and the Pax7CE/loxP-Le strains.
(F) Number of SCs identified by EM analysis in Pax7CE/loxP-Gu and Pax7CE/loxP-Le strains at different time points. Numbers include atypical SCs.
(G) Number of atypical SCs identified by reduced heterochromatin content and abnormal amounts of cytoplasm and organelles.
Abbreviations: M, myocyte; SC, satellite cell; IC, interstitial cell; CP, cytoplasm; pTAM, post TAM injection; cTAM, continuous TAM administration. Error bars
represent standard deviation of the mean (t test: **p < 0.01; ***p < 0.001). Scale bar: (A)–(C) = 2 mm. See also Figure S4.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem Cellsloss of Pax7 promotes formation of low numbers of atypical SCs
with irregular chromatin organization.
Pax7 Stimulates Proliferation of SCs in Culture
Since the Pax7loxP-Gu allele represented themost efficient means
to fully neutralize Pax7 activity, we employed this strain to gain
further insight into the role of Pax7 for self-renewal and expan-
sion of SCs. We found that inactivation of Pax7 in isolated SCs
(Cerletti et al., 2008) obtained from Pax7CE/loxP-Gu mice by acti-
vation of the Cre recombinase via 4OH-TAM or by infection of
Pax7loxP-Gu/loxP-Gu cells with Adeno-Cre mimicked the incom-
plete recombination of Pax7CE/loxP-Gu mice subjected to the 5-
day TAM regimen in vivo (Figure 5). Nevertheless, we observed
a significant decline of Pax7-positive cells, which went along594 Cell Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inwith a reduction of 5-ethynyl-20-deoxyuridine (EdU)-incorpo-
rating proliferating cells and a corresponding increase of non-
proliferating cells (Figures 5B–5D). Consistently, infection of
SCs derived from Pax7loxP-Gu/loxP-Gu mice with the Adeno-Cre
virus resulted in incomplete deletion of the Pax7 gene within a
5-day period, indicating a relatively sluggish recombination of
the Pax7 locus (Figures 5F–5K). Similar to the 4OH-TAM
treatment, we found a massive reduction of EdU-incorporating
Pax7loxP-Gu/loxP-Gu SCs after their infection with Adeno-Cre
compared to an Adeno-eGFP control virus (Figure 5I). Finally,
we knocked down Pax7 by RNAi or overexpressed Pax7 in puri-
fied wild-type SCs via lentiviral transduction (Figure S5). Expres-
sion of the Pax7 shRNA resulted in a rapid and efficient inhibition
of Pax7 expression within the 5-day cultivation period,c.
Figure 4. Loss of SCs and Impaired Skeletal Muscle Regeneration in Pax7CE/loxP-Le Mice Occurs Late after Cre Recombinase Activation
(A) HE staining of T.A. muscles at different time points after TAM treatment. CTX injections were performed as indicated following 5 days of TAM administration.
(B) Representative images of HE and X-gal-stained muscles of mice 240 days after Cre recombinase activation and 10 days after CTX injection. The number of
remaining lineage-traced SCs (arrowheads in upper panel) and their contribution to muscle regeneration (lower panel) is massively reduced after Pax7 inacti-
vation.
(C) Loss of SCs in Pax7CE/loxP-Le mice becomes apparent only late (60d) after Pax7 inactivation and reached a maximum at 240d.
Error bars represent standard deviation of the mean (t test: n.s. = not significant; **p < 0.01; ***p < 0.001). Scale bar: 50 mm.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem Cellsbypassing the delay of Cre-recombinase-mediated deletion.
Again, we observed significant reduction of cell cycle entry as
indicated by reduced EdU incorporation and increased differen-
tiation of SCs both in the presence and absence of fetal calf
serum (Figures S5D–S5G). In contrast, overexpression of Pax7
caused an increase in the number of EdU-incorporating Pax7-
positive SCs and a reduction of nonproliferating cells, as well
as an impairment of SC differentiation with and without mitogen
deprivation (Figures S5D–S5G), which is in line with previous re-
sults (Zammit et al., 2006).
To further analyze the potential of Pax7-deficient cells for
proliferation and differentiation, we isolated Pax7CE-lineage-
traced SCs by FACS from Pax7CE/loxP-Gu/Rosa26YFP and
Pax7CE/+/Rosa26YFP mice at different time points after comple-
tion of TAM administration. Similar to the in vitro results, recom-
bination was slow, as indicated by the gradual emergence of
YFP-expressing cells (Figure S6A). We did not see a decline of
permanently labeled Pax7mutant SCs 1d and 14d after standard
TAM treatment, confirming that SCs after deletion of Pax7
survive for several weeks in vivo in skeletal muscle. A decline
of Pax7CE/loxP-Gu/Rosa26YFP-lineage-traced cells occurred only
after 30d or after extended TAM treatment (Figures S6A and
S6B). FACS-isolated Pax7-deficient cells showed a decreasedCellrate of EdU incorporation (Figure S6C) and an enhanced pro-
pensity for differentiation (Figure S6D), corroborating the
assumption that remaining Pax7 mutant SCs proliferate poorly
but survive for several weeks.
Since we did not find any evidence for increased cell death of
adult SCs after inactivation of Pax7 in vitro and in vivo but
increased differentiation (Figures S5F and S5G and data not
shown), we assume that Pax7-deficient, hypoproliferative SCs
are mainly removed by differentiation into myocytes. This
conclusion is also supported by lineage tracing experiments,
which demonstrated differentiation of remaining Pax7 mutant
SCs into myotubes in vivo (Figure 4B) and in vitro after FACS
sorting (Figure S6D).
Myf5-Cre-Mediated Inactivation of Pax7 Leads to a
Postnatal Decline of SCNumber andEfficiently Prevents
Skeletal Muscle Regeneration
During the course of our experiments, we found that extended
activation of Cre recombinase in SCs for deletion of the Pax7
gene affected muscle regeneration to a much greater extent
than the short-term 5-day TAM treatment (compare Figure 2A–
2F to Figure 2G–2L), although the number of remaining SCs
was not reduced any further. Hence, we reasoned that Pax7Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inc. 595
Figure 5. Impaired Proliferation of Adult SCs after Inactivation of Pax7 in Culture
(A–E) FACS-purified SCs from Pax7CE/loxP-Gu mice were treated in culture with or without 4OH-TAM under high serum concentrations (A). Total number of SCs
after TAM-induced deletion of Pax7 (B). Number of Pax7-positive cells (C) and EdU-incorporating Pax7-positive cells (D and E) after addition of TAM. Cells were
analyzed after 6d of cultivation.
(F–J) Viral-mediated knockout of Pax7 in cultured SCs. FACS-sorted SCs from Pax7loxP-Gu/loxP-Gu mice were infected with Adeno-Cre and Adeno-eGFP viruses
24 hr after isolation to inactivate the Pax7 gene (F). Decreases of the total number of SC-derived cells (G), of Pax7-positive cells (H), and of EdU-incorporating
Pax7-positive cells (I and J) 6d after Adeno-Cre mediated deletion of Pax7 are shown.
Error bars represent standard deviation of the mean (t test: *p < 0.05; ***p < 0.001). Scale bar: 20 mm. See also Figures S5 and S6.
Cell Stem Cell
Pax7 Controls Adult Muscle Stem Cellsdoes not only control SC self-renewal and maintenance, but
must also play a role in expanding muscle stem cells, in which
the Myf5 locus is consistently active. To test this hypothesis we
used two different Myf5Cre knockin mouse strains (Myf5Cre-So
and Myf5Cre-Ke) that enable deletion of Pax7 in Myf5-expressing
cells (Haldar et al., 2007; Tallquist et al., 2000). The basic helix
loop helix (bHLH) transcription factor Myf5 is the earliest marker
of myogenic commitment during embryonic development (Braun
and Gautel, 2011). In adults, Myf5 is expressed in the majority of
SCs downstream of Pax7 (Kuang et al., 2007) and in proliferating,
satellite-cell-derived myoblasts (Cooper et al., 1999; Kuang
et al., 2007; Ustanina et al., 2007). In addition, it has been shown
that repopulation of the muscle stem cell niche is mainly
achieved by a subpopulation of SCs that have never expressed
Myf5, further supporting the idea that Myf5 regulates myogenic596 Cell Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Incommitment, but not the self-renewal properties, of muscle
stem cells (Kuang et al., 2007). Myf5Cre-So/Pax7loxP-Gu/loxP-Gu
mice were viable and fertile but consistently smaller compared
to Myf5Cre-So/Pax7loxP-Gu/+ littermates (Figure 6A). In situ hybrid-
izations revealed a complete absence of Pax7 expression in
somites of Myf5Cre/Pax7loxP-Gu/loxP-Gu embryos at E.10.5 while
expression in the neural tube and the head mesenchyme was
unaffected (Figure S7).
Surprisingly, we found a normal number of Pax7-positive SCs
during the first 10 weeks of postnatal development in Myf5Cre-So/
Pax7loxP-Gu/loxP-Gu mice (n = 3, SCs/100 nuclei, Myf5Cre-So/
Pax7loxP-Gu/loxP-Gu 0.433 ± 0.067; Myf5Cre-So/Pax7loxP-Gu/+
0.319 ± 0.095;Myf5Cre-So/Pax7+/+ 0.487 ± 0.077) (Figure 6B) indi-
cating that these cells were derived from a Myf5-independent
myogenic lineage (Gensch et al., 2008; Haldar et al., 2008).c.
Figure 6. Loss of SCs and Impairment of Muscle Regeneration after Deletion of Pax7 in Myf5-Expressing Cells
(A) Growth retardation of 28d Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice compared to Myf5Cre-So/Pax7loxP-Gu/+ and Myf5Cre-So/Pax7+/+ littermates. The growth retar-
dation persisted during postnatal life. (B) Numbers of Pax7-positive/CD34-positive SCs in flexor digitorum brevis (FDB) muscles of Myf5Cre-So/Pax7loxP-Gu/loxP-Gu
(n = 3), Myf5Cre-So/Pax7loxP-Gu/+ (n = 3), and Myf5Cre-So/Pax7+/+ (n = 3) at different postnatal stages relative to the total number of myonuclei. A reduction of SCs is
evident at 89d and thereafter. (B) Analysis of Pax7mRNA expression inMyf5Cre-So/Pax7loxP-Gu/loxP-Gumice during postnatal life in the T.A. (E). (C and D) Analysis of
Pax7 mRNA expression in Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice during postnatal life (D) and after CTX-induced regeneration in the T.A. (E). (E) Quantitative analysis
of SC numbers in Myf5Cre-So/Pax7loxP-Gu/loxP-Gu/MyoD(/) mice (striped) at an age of 100 days. Loss ofMyoD results in a further loss of Pax7-positive cells. Error
bars represent standard deviation of the mean (t test: n.s. = not significant; *p < 0.05; **p < 0.01; ***p < 0.001).
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Pax7 Controls Adult Muscle Stem CellsSimilar results were obtained using the Myf5Cre-Ke strain (Fig-
ure 6E). Obviously, the lack of Pax7 deletion in the population
of Myf5-negative myogenic progenitor cells allowed their
survival and expansion after birth, thereby replacing myogenic
cells in which Myf5Cre-So or Myf5Cre-Ke has been activated and
hence in which the Pax7 gene was deleted. Such Pax7-posi-
tive/Myf5-negative cells will activate the Myf5 locus during later
postnatal life to generate Pax7-positive/Myf5-positive SCs
(Kuang et al., 2007).
Along this line, Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice older than
56d displayed a decreased number of SCs compared to con-
trols and reduced expression levels of Pax7 mRNA in skeletal
muscles (Figures 6B and 6C). Myotubes of Myf5Cre-So/
Pax7loxP-Gu/loxP-Gu mice only rarely contained Pax7-positive
SCs (n = 15, SCs/100 nuclei, Myf5Cre-So/Pax7loxP-Gu/loxP-Gu
0.047 ± 0.017; Myf5Cre-So/Pax7loxP-Gu/+ 0.213 ± 0.048;
Myf5Cre-So/Pax7+/+ 0.400 ± 0.08) or CD34-positive SCs (SCs/
100 nuclei, Myf5Cre-So/Pax7loxP-Gu/loxP-Gu 0.1 ± 0.03, n = 15;
Myf5Cre-So/Pax7loxP-Gu/+ 0.311 ± 0.032, n = 15; Myf5Cre-So/
Pax7+/+ 0.474 ± 0.063, n = 13) (Figure 6B), clearly indicating
that SCs are replenished by committed, Myf5-expressing
cells during later stages of postnatal development. To an-
alyze whether Myf5-negative, MyoD-positive myogenic
progenitor cells give rise to Pax7-positive SCs, we generated
Myf5Cre-Ke/Pax7loxP-Gu/loxP-Gu/MyoD(/) mice. Interestingly, weCellobserved a further decline, but not a complete loss, of Pax7-pos-
itive SCs in 110d Myf5Cre-Ke/Pax7loxP-Gu/loxP-Gu/MyoD(/) mice
compared to theMyf5Cre-Ke/Pax7loxP-Gu/loxP-Gu strain (Figure 6E).
From these data we concluded that an embryonic myogenic cell
population that depends on MyoD but does not express Myf5
was able to partially compensate for SCs that had expressed
Myf5. The presence of Pax7-positive SCs in Myf5Cre-Ke/
Pax7loxP-Gu/loxP-Gu/MyoD(/) mice suggests that a small amount
of SCs have never expressed Myf5 or MyoD during develop-
ment, although both genes seem to be activated in virtually all
cells that populate or repopulate the SC niche.
To further investigate the role of Pax7 in expanding, Myf5-
expressing SCs, we induced muscle regeneration by CTX in-
jection in 56d, 90d, and 315d Myf5Cre-So/Pax7loxP/loxP-Gu and
Myf5Cre-Ke/Pax7loxP-Gu/loxP-Gu mice before and after decline of
SC numbers. Most significantly, we observed a severe impair-
ment of skeletal muscle regeneration at all stages irrespective
of the number of remaining SCs (Figure 7 and data not shown).
Only a few thin myotubes emerged in damaged muscles, which
weremainly characterized by accumulation of connective tissue,
while regeneration occurred normally in Myf5Cre-So/Pax7loxP-Gu/+
mice (Figures 7C, 7F, 7I, and 7J). Expression of Pax7 mRNA was
virtually completely lost in Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice
after induction of muscle injury, corroborating the efficient dele-
tion of the Pax7 gene during amplification of myogenic cellsStem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inc. 597
Figure 7. Age-Independent Impairment of Muscle Regeneration after Deletion of Pax7 in Myf5-Expressing Cells
Morphological analysis of T.A. muscles of Myf5Cre-So/Pax7loxP-Gu/loxP-Gu and Myf5Cre-So/Pax7loxP-Gu/+ mice of different ages with and without CTX injections to
induce muscle regeneration.
(A–F) HE staining of T.A. muscles of 8-week-old mice (n = 3) 14 days after CTX injection.
(G–L) HE staining of T.A. muscles of 45-week-old mice (n = 3) 14 days after CTX injection. Myf5Cre-So-mediated deletion of Pax7 resulted inmassive impairment of
myofiber formation and increased fibrosis in regenerating muscles while no morphological abnormalities are apparent in nondamaged muscles. Cross-sections
through nondamaged soleus muscles are shown as control (A, D, G, and J). Scale bar: overview = 20 mm; magnification = 5 mm. See also Figure S7.
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Pax7 Controls Adult Muscle Stem Cells(Figure 6D). Importantly, these data correspond to the results of
continuous stimulation of Cre recombinase activity for inactiva-
tion of Pax7 using Pax7CE-mice. Taken together, our data reveal
that aside from its function in the maintenance of SCs, Pax7
plays an essential role for the expansion of Myf5-expressing
myogenic cells, thereby enabling tissue regeneration.
DISCUSSION
Here, we describe that Pax7 is necessary for the maintenance
of muscle SCs in adult mice and define a crucial function of
Pax7 for expansion of SCs after injury. We also demonstrate
that replenishment of muscle stem cells from Myf5-expressing
myogenic cells requires Pax7, which is compromised but not
completely blocked by the absence of MyoD, suggesting that
muscle stem cells are partially derived from cells not expressing
Myf5 or MyoD during development. Furthermore, we found that
a relatively small number of muscle stem cells efficiently regen-
erated skeletal muscles after inactivation of the Pax7 gene in
the majority of SCs.
The efficient regeneration of skeletal muscle after 94.3%
reduction of SCs following inactivation of Pax7 was surprising
since several previous studies demonstrated that toxin-mediated
ablation of themajority of SCs leads to complete failure ofmuscle
regeneration (Lepper et al., 2011; Murphy et al., 2011; Sambasi-
van et al., 2011). Importantly and in contrast to the studies
describing toxin-mediated ablation of Pax7-expressing SCs,
here we applied a gene-targeting approach to delete the Pax7598 Cell Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Ingene. It is conceivable that toxin-expressing SCs are not killed
immediately but fuse to other myoblasts, which might potentiate
effects in a kind of modified bystander effect that becomes rele-
vant when cells form syncytia (Massuda et al., 1997). Alterna-
tively, the diphtheria-toxin-based approach, but not the gene
deletion strategy, might activate processes in muscles that inter-
ferewith regeneration. Furthermore, we found that deletion of the
Pax7 gene resulted in a gradual loss of SCswhile activation of the
diphtheria toxin will lead to cell death within a relatively narrow
timewindow,whichmight prevent adaptive processes in skeletal
muscles (Gensch et al., 2008). Finally, it cannot be ruled out that
Pax7-negative, CD34-positive SCs initially contribute to the
regeneration process, although our finding that continuous stim-
ulation of Pax7 gene deletion before and after injury prevented
regeneration argues against such a possibility.
It seems likely that the loss of SCs and the regeneration deficit
of adult Pax7 mutant SCs was missed in a previous study (Lep-
per et al., 2009) due to various reasons: muscle regeneration was
assayed within 10d after injury, addressing short-term effects of
Pax7 inactivation. Since the loss of SCs was protracted for
several weeks in the Pax7loxP-Le strain after completion of TAM
treatment, immediate analysis of mutant mice after deletion of
Pax7 might have masked the effects of Pax7 on muscle stem
cell maintenance and tissue regeneration. In addition, the
Pax7loxP-Le allele produces a shortened mRNA that is able, by
overexpression in HEK293T cells, to generate a truncated pro-
tein lacking the paired-box domain but still containing the home-
odomain, which was recently described to play a pivotal role inc.
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Pax7 Controls Adult Muscle Stem Cellsmediating actions of Pax7 during adult myogenesis (Soleimani
et al., 2012). Such a protein might confer a residual biological ac-
tivity of the Pax7loxP-Le allele responsible for the delayed decline
of SCs compared to the Pax7loxP-Gu strain. Yet, Pax7loxP-Le mice
eventually also suffer from a dramatic decrease of SCs and
impairment of skeletal muscle regeneration, but only 150d to
240d after the initial TAM treatment.
EM-based analyses of SC numbers did not only provide
unequivocal evidence for the dramatic reduction of SCs after
inactivation of Pax7, but also revealed that remaining Pax7
mutant SCs show reduced heterochromatin condensation.
This observation was particularly intriguing since Pax3, a tran-
scription factor closely related to Pax7, was recently described
to safeguard heterochromatin integrity in collaboration with
another Pax gene family member, Pax9, in mouse embryonic
fibroblasts (Bulut-Karslioglu et al., 2012). Interestingly, the
authors of the study speculated that other transcription factors
such as Pax7 might mediate heterochromatin silencing in mus-
cle cells by recruitment of histone methyltransferases to reiter-
ated transcription factor binding sites within heterochromatic
repeat regions, thereby generating H3K9me3 repressive chro-
matin marks facilitating heterochromatin condensations. So
far, mainly HMTs such as the Wdr5-Ash2L-MLL2 complex,
which directs activating H3K4 histone modifications, were found
to cooperate with Pax7 (McKinnell et al., 2008), but it seems
likely that other HMTs such as SUV39H1, Clr4p, DIM-5, Su(var)
3-9 or SETDB1, and G9 (Karimi et al., 2011; Krauss, 2008; Shin-
kai and Tachibana, 2011) also interact with Pax7. Future exper-
iments will show how Pax7 specifically affects global chromatin
organization in SCs and whether such atypical SCs possess
distinct biological properties.
The loss of SCs after inactivation of the Pax7 gene in adult
mice raises the question about the underlying mechanism.
We and others have proposed that the progressive loss of
SCs in newborn constitutive Pax7 mutants is caused by a pro-
liferative defect in SCs (Oustanina et al., 2004; Relaix et al.,
2005). This finding was later refined, demonstrating that the
absence of Pax7 in newborn mice has effects on the cell cycle
and leads to cell death (Relaix et al., 2005), although this
conclusion does not necessarily need to hold true for adult
SCs. Lastly, lineage tracing of Pax7-positive cells demon-
strated that mutant cells are more readily incorporated into
myofibers than control cells during the perinatal period (Lepper
et al., 2009). In the current study we demonstrated that elimina-
tion of Pax7 in adult SCs in vitro and in vivo strongly reduced
the number of proliferating SCs. Since we did not find evidence
for increased cell death or apoptosis in cultures of Pax7-defi-
cient SCs or in skeletal muscles but detected robust differenti-
ation of mutant SCs into MyHC-positive myotubes, we favor the
hypothesis that the loss of Pax7-deficient SCs in adult mice is
mainly caused by differentiation, although we cannot rule out
an enhanced rate of apoptosis in vivo over an extended time
period.
The decline of SC numbers in Myf5Cre-So/Pax7loxP/loxP mice
after postnatal day 56 and the massive impairment of skeletal
muscle regeneration in these mice indicate that Myf5-positive
SCs contribute to Pax7-dependent maintenance and expansion
of muscle progenitor cells in adult mice. Most likely, lack of Pax7
in activated SCs and/or satellite-derived myogenic cells leads toCellcessation of cell proliferation, thereby interfering with SC
renewal and expansion, which prevents muscle regeneration.
Alternatively, it is possible that the lack of Pax7 expression in
Myf5-expressing cells puts a considerable strain on SCs, which
do not expressMyf5, thereby leading to an exhaustion of this cell
population and reduced contribution to SC renewal and skeletal
muscle regeneration. While this argument might hold true for
physiological aging, it seems less valid for regenerating muscles
of Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice, which fail to restore mus-
cle tissue before a drop of SC numbers is apparent (Figure 7).
Hence, we believe that one is dealing with two different phenom-
ena in Myf5Cre-So/Pax7loxP-Gu/loxP-Gu mice: (1) continuous decline
of SCs during physiological aging due to intermittent activation
of the Myf5 locus driving Cre recombinase expression. This will
result in ongoing deletion of Pax7 in SCs and continuous decline
of SC numbers, which becomes apparent between postnatal
days 56 and 89. (2) Massive impairment of SC expansion due
to activation of Myf5-Cre expression at early stages of muscle
regeneration, resulting in inactivation of the Pax7 gene. The
assumption that Pax7 plays a crucial role for the expansion of
SCs after injury-induced activation is in line with strong impair-
ment of muscle regeneration after continuous stimulation of
Cre recombinase activity, while temporary induction of Cre
recombinase activity before muscle injury had only little effects,
probably because of compensatory expansion of the remaining
residual population of Pax7-positive SCs.
The relatively late decline of SCs in Myf5Cre-So/
Pax7loxP-Gu/loxP-Gu and Myf5Cre-Ke/Pax7loxP-Gu/loxP-Gu mice
between postnatal days 56 and 89 suggests that Pax7-positive
SCs are initially derived from myogenic progenitor cells, which
do not express Myf5. Alternatively, it seems possible that a
Pax7-positive myogenic progenitor cell population depending
on MyoD amplifies and compensates for cells that are derived
from Myf5-dependent muscle progenitor cells. In fact, we
observed a further reduction of Pax7-positive SCs in
Myf5Cre-So/Pax7loxP-Gu/loxP-Gu/MyoD(/) compound mutant
mice. The lack of the MyoD gene in this strain prevents genera-
tion of MyoD-dependent muscle progenitor cells. Since we did
not observe a complete loss of Pax7-positive SCs, we
concluded that a part of Pax7-positive SCs is derived from
myogenic cells, which require neither Myf5 nor MyoD but never-
theless give rise to Pax7-positive SCs, albeit at a lower rate. This
conclusion corroborates a previous report describing a cell pop-
ulation that expresses the transcription factors Pax3 and Pax7
and adopts a SC position characteristic of progenitor cells in
postnatal muscle (Relaix et al., 2005).
Ultimately, we propose that in aging mice a significant amount
of SCs is generated from a pool of amplifying, Myf5-expressing
muscle stem cells in a Pax7-dependent manner, contributing to
the heterogeneity of the muscle stem cell population. Similar
networks that do not depend on the classical hierarchical
mode of self-renewal and differentiation but on neutral competi-
tion between symmetrically dividing stem cells have recently
been described for stem cell maintenance in the mouse intestine
(Snippert et al., 2010) and for the self-renewal of radial glia-like
neural stem cells (Bonaguidi et al., 2011). The concept of non-
hierarchical maintenance and expansion of muscle stem cells
revises previous ideas and offers new ways to exploit stem cells
for improved regeneration of muscle tissues.Stem Cell 13, 590–601, November 7, 2013 ª2013 Elsevier Inc. 599
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Animals
The strategy to generate the Pax7loxP-Gu allele is described in Figure S1. Gen-
eration of Pax7CE (Lepper et al., 2009), Rosa26YFP (Srinivas et al., 2001), CMV-
Cre (Schwenk et al., 1995), Myf5Cre-So (Tallquist et al., 2000), and Myf5Cre-Ke
(Haldar et al., 2007) mice has been described previously. TAM (Sigma) was
administered intraperitoneally at 3 mg per 40 g body weight per injection.
CTX (0.06 mg/ml, Sigma) was injected into T.A. muscles in a volume of
50 ml. All animal experiments were done in accordance with the Guide for
the Care and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996) and according to
the regulations issued by the Committee for Animal Rights Protection of the
State of Hessen (Regierungspraesidium Darmstadt).
PCR Genotyping, RT-PCR, Immunofluorescence, and Histology
Primers used for genotyping and RT-PCR are listed in the Supplemental
Experimental Procedures. T.A. muscles were frozen in isopentane/liquid
nitrogen and cryosectioned at 8 mm. Cryosections were counterstained with
Hematoxylin/Eosin (Chroma) using established techniques. Antibodies for
immunofluorescence staining of cryosections are listed in the Supplemental
Experimental Procedures. EdU incorporation was visualized using the Click-
iT Imaging Kit (Invitrogen).
EM
Identification of SCs in skeletal muscle by EM was based on cell size, content
of heterochromatin, and position to basal lamina and sarcolemma as outlined
before (Oustanina et al., 2004).
Cell Culture
FACS-based isolation of SCs was accomplished with a FACSAriaIII (BD Bio-
sciences) using antibodies listed in the Supplemental Experimental Proce-
dures. For FACS-based SC isolation, hind limb and trunk muscles were
minced, digested with 100 CU Dispase (BD) and 0.2% type II collagenase
(Worthington Biochemicals), and filtered through 100 mm, 70 mm, and
40 mm cell strainers (BD). After lysis of red blood cells by hypotonic shock,
the cell suspension was loaded onto a 30% / 70% Percoll (Sigma) gradient.
Mononuclear cells were located in the interphase between 30% and 70%
Percoll while debris and dead cells were situated on top of the 30% phase.
Next, mononuclear cells were washed with PBS, blocked with 1% FCS,
and immunostained with fluorescence coupled primary antibodies to exclude
CD11b PE-Cy7, CD45 PE, and CD31 PE cells and to include mCadherin APC
and CD34 Alexa-450-expressing cells. Unstained cells were used to distin-
guish autofluorescence background from positive signals. SCs were cultured
on Matrigel-coated 96- or 384-well mClear plates (BD Biosciences, Greiner)
as described previously (Ustanina et al., 2007) and subjected to immunoflu-
orescence staining. 4OH-TAM (0.4 mM, Calbiochem) was added to the
medium after plating of cells and was exchanged daily. EdU (Invitrogen)
was added to the culture 3 hr before fixation in a final concentration of
40 mM. Detection of EdU was done with Alexa Fluor 594 (Invitrogen) following
standard protocols. Image acquisition and analysis were performed on
ImageXpress micro high throughput microscope with MetaXpress software
(Molecular Devices).
Muscle Fiber Size and Myotube Analysis
Digital images of Hematoxylin/Eosin-stained sections were processed by
ImageJ software (NIH) measuring the area of visually localized fibers (>400
fibers per animal). Myotubes were isolated as described (Oustanina et al.,
2004). SCs situated on myotubes were identified by being immunostained
with Pax7, CD34, and CalcR antibodes (see Supplemental Experimental Pro-
cedures). Statistical analyses were performed using Microsoft Excel and
GraphPad Prism software.
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